VEGFA and macular retinal edema: Elevated production of vascular endothelial growth factor (VEGF) was recently shown to be associated with DME3, and anti-VEGF agents, including ranibizumab and aflibercept, significantly reduce macular edema and subsequently improve visual acuity in DME4–6.